JeremyMShefnerMDPhD

Neurology • Phoenix, AZ

Neuromuscular Medicine, Neurophysiology

Kemper and Ethel Marley Professor and Chair of Neurology Barrow Neurological Institute

Join to view full profile

Dr. Shefner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shefner's full profile

Already have an account?

Office
240 W Thomas Rd
Ste 400
Phoenix, AZ 85013
Phone+1 602-406-6262

Fax+1 602-406-6261

Education & Training

Brigham and Women's Hospital/Children's Hospital/Harvard Medical SchoolFellowship, Clinical Neurophysiology, 1988 - 1990
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1987 - 1988
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1984 - 1986
Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 1983 - 1984
Northwestern University The Feinberg School of MedicineClass of 1983

Certifications & Licensure

AZ State Medical License 2014 - 2026
MA State Medical License 1985 - 2017
NY State Medical License 1996 - 2016
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Neuromuscular Medicine

Awards, Honors, & Recognition

America's Best Doctors Best Doctors, 2007-2016
Sheila Essey Award for ALS Research American Academy of Neurology, ALS Association, 2014
America's Top Doctors Castle Connolly, 2009-2014

Clinical Trials

A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS Start of enrollment: 2005 Oct 01
Completed
Phase 2
A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS
Withdrawn
Phase 2
Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials Start of enrollment: 2007 May 01
Completed
A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2010 Mar 01
Completed
Phase 2
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2011 Jun 01
Completed
Phase 2
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2011 Nov 01
Completed
Phase 2
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2012 Oct 01
Completed
Phase 2
Clinical Trial Nuedexta in Subjects With ALS Start of enrollment: 2013 Apr 01
Completed
Phase 2
Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Aug 01
Completed
Phase 2
Study of Electrical Impedance Myography (EIM) in ALS Start of enrollment: 2013 Nov 01
Completed
A Trial of Tocilizumab in ALS Subjects Start of enrollment: 2015 Nov 01
Completed
Phase 2
ALS Testing Through Home-based Outcome Measures Start of enrollment: 2017 Feb 22
Completed
Ciprofloxacin/Celecoxib Combination in Patients With ALS Start of enrollment: 2019 Dec 09
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Access for ALL in ALS: A large-scale, inclusive, collaborative consortium to unlock the molecular and genetic mechanisms of amyotrophic lateral sclerosis.
James D Berry, Sabrina Paganoni, Matthew B Harms, Neil Shneider, Jinsy Andrews
Muscle & Nerve. 2024-12-01
Guidance for clinical management of pathogenic variant carriers at elevated genetic risk for ALS/FTD.
Michael Benatar, Terry D Heiman-Patterson, Johnathan Cooper-Knock, Daniel Brickman, Kaitlin B Casaletto
Journal of Neurology, Neurosurgery, and Psychiatry. 2024-11-21
Plasma neurofilament analysis in VITALITY-ALS.
Tyrell J Simkins, Stuart Kupfer, Fady I Malik, Lisa Meng, Stacy A Rudnicki
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2024-11-08

Journal Articles

Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis
Brian J Wainger, Nicholas J Maragakis, Richard Bedlack, Namita A Goyal, Seward B Rutkove, Michael H Rivner, Stephen A Goutman, Shafeeq S Ladha, Elizabeth A Mauricio, R..., JAMA Neurology
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Sabrina Paganoni, Michael A Elliott, Samuel Maiser, Margaret A Owegi, Stephen A Goutman, Carlayne E Jackson, Jeffrey D Rothstein, Edward J Kasarskis, Liberty Jenkins, ..., The New England Journal of Medicine

Press Mentions

NeuroSense Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal DegenerationSeptember 19th, 2022
Desperate Patients Want a New ALS Drug. The FDA Is Not Sure It WorksSeptember 6th, 2022
AcuraStem's Development Candidate AS-202 Demonstrates Excellent Safety and Potency in Preclinical Models Representing Diverse Forms of ALSDecember 15th, 2021
Join now to see all